

Rapid Process Development Enabled By Automated, Single Use High Throughput Technologies

Christopher Kistler, Bioprocess Development, Merck & Co., Inc.,
Kenilworth, NJ

Efforts continue to speed the progress of new biologics from discovery through preclinical development to product launch. This is challenged by the move to novel modalities and managing the existing pipeline of products with limited resources. To provide rapid and right first time development, Merck Bioprocess Development applied automation and single use technologies from end to end, covering from cell line development to purified drug substance.